GHRP-6 vs Hexarelin

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicGHRP-6Hexarelin
What it is

A synthetic hexapeptide amide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2), also recorded as hexapeptide-2 and SK&F-110679, according to FDA’s substance registry.3

A synthetic hexapeptide amide containing 2-methyl-D-tryptophan, recorded as examorelin, hexarelin and EP-23905 in FDA’s substance registry.2

FDA status

Not FDA-approved

No FDA approval reported; on FDA’s compounding safety-risk list (category 2)1

No FDA approval is reported in the sources reviewed here. Since September 29, 2023, FDA has listed GHRP-6 in category 2 under its interim policy for outsourcing facilities, for substances that may present significant safety risks.1

Is GHRP-6 FDA-approved?

Not FDA-approved

No FDA approval reported1,2

No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page, current as of April 22, 2026, does not list hexarelin.1,2

Is hexarelin FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.4

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. GHRP-6 is not among them.4,5

Not among the six peptides the policy lists.4

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Hexarelin is not among them.4,5

FDA compounding safety-risk page

Listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, lists GHRP-6 in category 2 under the interim policy for outsourcing facilities (section 503B) since September 29, 2023, citing possible immune reactions from aggregation and impurities.1

Not listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list hexarelin, either in category 2 or among withdrawn nominations.1

Kinds of studies cited

Limited human data

  • Small, short, or incompletely reported human study A 2013 pharmacokinetic study in nine healthy men, which measured how quickly GHRP-6 is distributed and cleared, without a comparison group.6

Smaller controlled human trials

  • Controlled human trial A placebo-controlled study in seven healthy young volunteers that measured sleep and night-time hormone levels after hexarelin (2004).7
  • Small, short, or incompletely reported human study A one-day study in six healthy young men measuring 24-hour hormone release after repeated hexarelin, without a placebo group (2002).8
Records collected

0 ClinicalTrials.gov records and 25 PubMed records collected

0 ClinicalTrials.gov records and 24 PubMed records collected

Area of study

Hormones3

Hormones7,8

Latest dated events
  1. FDA’s compounding safety-risk page, as last updated, keeps GHRP-6 in category 2.1
  2. FDA places GHRP-6 in category 2 under its 503B interim compounding policy, according to its safety-risk page.1
  3. A pharmacokinetic study of GHRP-6 in nine healthy men is published.6
  1. FDA’s compounding safety-risk page is last updated; it does not list hexarelin.1
  2. A placebo-controlled study of hexarelin and sleep in seven healthy volunteers is published.7
  3. A one-day study of repeated hexarelin in six healthy men is published.8

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  2. 2
    Examorelin (hexarelin) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  3. 3
    GHRP-6 (hexapeptide-2) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  4. 4
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  5. 5
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers (2013) · PMID 23099431 ↗

    European Journal of Pharmaceutical Sciences · Official source · Source checked November 15, 2026

  7. 7
    Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers (2004) · PMID 15177700 ↗

    Psychoneuroendocrinology · Official source · Source checked November 15, 2026

  8. 8
    Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans (2002) · PMID 11888836 ↗

    European Journal of Endocrinology · Official source · Source checked November 15, 2026